Filed Pursuant to Rule 424(b)(3)
                                                     Registration No. 333-106294

PROSPECTUS SUPPLEMENT NO. 7
TO PROSPECTUS DATED OCTOBER 14, 2003

                                  $200,000,000
             2.5% CONTINGENT CONVERTIBLE SUBORDINATED NOTES DUE 2033
                                       AND
                              CLASS A COMMON STOCK
                      ISSUABLE UPON CONVERSION OF THE NOTES


                        (K-V PHARMACEUTICAL COMPANY LOGO)


                           K-V PHARMACEUTICAL COMPANY

                                   ----------

         This document supplements our prospectus dated October 14, 2003 (the
"prospectus"), relating to $200,000,000 aggregate principal amount of our 2.5%
Contingent Convertible Subordinated Notes Due 2033 (the "Notes") and the Class A
common stock issuable upon conversion of the Notes. You should read this
prospectus supplement in conjunction with the accompanying prospectus, which is
to be delivered by selling securityholders to prospective purchasers along with
this prospectus supplement and any other prospectus supplements. The information
in the following table supplements the information under the caption "Selling
Securityholders" in the prospectus by supplementing the information contained in
the prospectus with the information contained in this Supplement No. 7 with
respect to the securityholder listed below.



                                              AGGREGATE                         CLASS A COMMON
                                              PRINCIPAL                             STOCK          CLASS A COMMON
                                               AMOUNT         PERCENTAGE OF      BENEFICIALLY          STOCK
                                            OF NOTES THAT         NOTES          OWNED BEFORE        REGISTERED
                    NAME                     MAY BE SOLD       OUTSTANDING      CONVERSION (1)         HEREBY
----------------------------------------   ---------------   ---------------    ---------------   ---------------
                                                                                      
Deutsche Bank Securities Inc.(2) .......   $     5,000,000             2.500%                 0           217,297
                                           ---------------   ---------------    ---------------   ---------------
         Subtotal ......................   $     5,000,000             2.500%                 0           217,297
                                           ===============   ===============    ===============   ===============


----------

(1)  The information presented assumes that any future transferee from any
     holder does not beneficially own any Class A common stock, other than Class
     A common stock into which the Notes are convertible at the conversion rate
     of 43.4594 shares per $1,000 principal amount of the Notes.

(2)  Deutsche Bank Securities Inc. served as one of the managing underwriters in
     our public offering of 4,600,000 shares of Class A common stock in July
     2002, and as an initial purchaser in the private placement of the Notes. It
     received customary compensation for those services.

         Investing in the Notes and the Class A common stock issuable upon their
conversion involves certain risks. See "Risk Factors" beginning on page 7 of the
accompanying prospectus.

         Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of the Notes or the Class A common stock
available upon conversion of the Notes or passed upon the adequacy or accuracy
of this prospectus supplement or the accompanying prospectus. Any representation
to the contrary is a criminal offense.

            The date of this prospectus supplement is March 18, 2004.